WADA commends Endocrine Module initiative spearheaded by International Testing Agency


The World Anti-Doping Agency (WADA) is pleased to share details about its ongoing collaboration with the International Testing Agency (ITA) regarding the effective use of the Endocrine Module of the Athlete Biological Passport (ABP). 

In July 2023, WADA published its new ABP Guidelines, which were updated to incorporate the Endocrine Module of the ABP. This new module collects information on markers of human growth hormone (hGH) doping. 

In the lead-up to the Paris 2024 Olympic Games (Paris 2024), the ITA initiated the targeted launch of the Endocrine Module in collaboration with WADA. This initiative involves several Anti-Doping Organizations (ADOs), including the International Skating Union (ISU), the Athletics Integrity Unit (AIU), the Agence française de lutte contre le dopage (AFLD), the United States Anti-Doping Agency (USADA), and UK Anti-Doping (UKAD).  

Dr. Reid Aikin, Associate Director, Athlete Biological Passport, said: “This collaborative initiative, which focuses on rapid implementation of the Endocrine Module and establishment of athlete profiles across various sports and disciplines, is a great example of how Anti-Doping Organizations should approach using the Endocrine Module. Targeted testing of athletes who are likely to attend Paris 2024 will lay the foundation for a robust anti-doping program at the Games, which will be delivered by the ITA. WADA commends the ITA for its initiative in prioritizing this useful tool in the lead-up to Paris 2024.   

“The Endocrine Module is a good example of how WADA, in close collaboration with key stakeholders, is taking steps to proactively develop the ABP as a key anti-doping tool by broadening the types of substances it is able to detect. We encourage Anti-Doping Organizations around the world to take advantage of the Endocrine Module as part of their overall testing strategy. The months leading up to the 2024 Olympic Games provide an excellent opportunity to prioritize testing for this module.” 

About the Endocrine Module 

The Endocrine Module aims to identify hGH abuse as well as use of hGH analogs, fragments and releasing factors categorized under Section S2.2 of the Prohibited List. This module may also indicate use of insulin-like growth factor-I (IGF-I), categorized under Section S2.3 of the Prohibited List. 

Should you have any questions regarding the Endocrine Module, please send them to